

ORIGINAL ARTICLE

Antibacterial Activity of *Solenostemma argel* Extracts Against Extended-spectrum β -lactamase Producing *Klebsiella pneumoniae*

¹Sherin M.A. Sharaf, ²Hanaa T.A. Ali, ²Mohamed G. Salah*, ²Zeinat Kamel

¹Department of Microbiology, Egyptian Drug Authority (EDA), Giza, Egypt

²Botany and Microbiology Department, Faculty of Science, Cairo University, 12613 Giza, Egypt

ABSTRACT

Key words:

ESBLs, *Klebsiella* species, antibiotic resistance, antimicrobial activity, *Solenostemma argel*

*Corresponding Author:

Mohamed Gamal Salah
²Botany and Microbiology
Department, Faculty of
Science, Cairo University,
12613 Giza, Egypt
farahat@sci.cu.edu.eg

Background: Extended-spectrum β -lactamases (ESBLs) can hydrolyze various types of β -lactam antibiotics. Therefore, infections caused by ESBL-producing bacteria pose a significant challenge to clinical patient care. **Objective:** This study aimed to assess the prevalence of ESBL-producing *Klebsiella pneumoniae* (ESBL-Kp) and evaluate the antibacterial potential of *Solenostemma argel* extracts against these isolates. **Methodology:** 200 clinical *Klebsiella* spp. isolates were identified by MALDI-TOF, and the Vitek2 system determined the antibiograms of *K. pneumoniae*. Phenotypic detection of ESBL was conducted using CHROMagar ESBL and the molecular characterization of *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes was carried out by polymerase chain reaction (PCR). In addition, methanolic and ethanolic extracts of *S. argel* were prepared and their antibacterial activity was investigated. **Results:** *K. pneumoniae* isolates exhibited remarkable resistance to cefuroxime (83.9%), ciprofloxacin (58.3%), ceftazidime (55.3%), aztreonam (44%), and cefepime (36.3%), respectively. Moreover, results of the phenotypic detection of ESBL revealed that 28.5% of *K. pneumoniae* isolates produced ESBLs and the molecular characterization showed that 100, 87.5, and 45.8% of ESBL-Kp isolates were positive for *bla*_{SHV}, *bla*_{CTX-M} and *bla*_{TEM} genes, respectively. Furthermore, the methanolic extract of *S. argel* exhibited promising antioxidant and antibacterial activity against ESBL-Kp with minimum inhibitory concentration (MIC) values ranged from 1 to 16 μ g/mL. **Conclusion:** This investigation shed light on the elevated levels of resistance among clinical *K. pneumoniae* isolates accompanied by the acquisition of the *bla*_{SHV} gene and verified the potent antibacterial activity of *S. argel* against ESBL-producing *K. pneumoniae*, suggesting the potential application of its methanolic extract in combating ESBL-Kp.

INTRODUCTION

In recent years, enterobacteria have emerged as one of the main causes of nosocomial and community-acquired infections¹. Though, being an integral part of the intestinal microbiota, *Klebsiella pneumoniae* can easily become a pathogen causing various extraintestinal infections, such as bacteremia, pneumonia, urinary tract, central nervous system, soft tissue, wound, and other invasive infections². Generally, aminoglycosides, cephalosporins, monobactams, and carbapenems are among the first choices to treat these infections³. Unfortunately, the spread of ESBL strains diminishes the efficacy of β -lactams and threatens public health⁴. It has been thought that the excessive use and misuse of antibiotics and the genetic plasticity of these bacteria have caused the emergence of highly resistant strains⁵. The ability of these bacteria to resist the existing antibiotics by changing their structures and lifestyle has caused an emerging threat to combat their infections⁶. It has been reported that the presence of

*bla*_{TEM} and *bla*_{CTX-M} genes in ESBL-producing bacterial isolates are associated with considerable resistance to β -lactams and third-generation cephalosporins⁷.

For these reasons, natural alternatives to antibiotics are being explored as potential treatments for bacterial infections as a potential effective strategy against the multidrug-resistant bacteria crisis⁸. Alternatives to conventional antibiotics could reduce the selective pressure for the development of antibiotic resistance. Many substitute techniques can be used to eradicate antibiotic-resistant bacteria, including phage therapy, antimicrobial peptides (AMPs), antibody therapies, and plant-based compounds⁹. In this regard, medicinal plants have been utilized in the ancient folk medicine to cure a wide range of illnesses because they contain active ingredients that may have antibacterial properties¹⁰. Numerous plant species, extracts, and secondary metabolites have been described as promising alternatives for inhibiting the growth of pathogenic bacteria¹⁰. The main advantage of using phytochemicals for antimicrobial purposes is their molecular

promiscuity, or their capacity to interact with several variables¹¹. A variety of phytochemical substances, including alkaloids, coumarins, flavonoids, essential oils, phenolics, polypeptides, terpenoids, and tannins, are abundant in medicinal plants¹¹. Among the medicinal plants, argel (*Solenostemma argel* Hayne) is an interesting herbal plant abundantly spread throughout North Africa. Argel's leaves, bark, and stems have a variety of medicinal uses and have long been used to cure various illnesses, including diabetes, pain, respiratory tract infections, heart conditions, gastrointestinal issues, urinary tract infections, and kidney, and liver diseases¹². Previous studies have explored the powerful antimicrobial efficacy of argel extracts against wide array of pathogenic bacteria, including *Staphylococcus aureus*, *Porphyromonas gingivalis*, *Salmonella typhimurium*, and *Escherichia coli*¹³. Even though argel has high quantities of phenolics with antioxidant and antimicrobial potentials, reports showing its activity against ESBL-*Kp* isolates are scarce. Hence, investigation was carried out to uncover the prevalence of ESBL-coding genes in *K. pneumoniae* and determine the antibacterial efficacy of ethanolic and methanolic extracts of argel against ESBL-*Kp*.

METHODOLOGY

Identification of bacterial isolates

In this study, we investigated 200 non-repetitive clinical *Klebsiella* spp. strains that were obtained from the Kasr Al Ainy Hospital's Microbiological Laboratory, Egypt, and identified to the genus level in

our previous work¹⁴. The matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) was utilized to identify *Klebsiella* isolates as described previously¹⁵.

Antimicrobial susceptibility testing

The antibiogram of all *K. pneumoniae* isolates was determined by the VITEK 2[®] automated equipment (bioMérieux, France) with Vitek2[®] Gram Negative Susceptibility cards (AST-GN83). The tested antimicrobials were ampicillin, piperacillin-tazobactam, amoxicillin-clavulanate, ampicillin-sulbactam, cefoxitin, cefuroxime, cefotaxime, ceftazidime, cefepime, aztreonam, amikacin, gentamicin, ciprofloxacin, co-trimoxazole, meropenem, and nitrofurantoin.

Phenotypic detection of ESBLs using CHROMagar ESBL

Each *K. pneumoniae* isolate was inoculated on CHROMagar ESBL, incubated at 37 °C for 18–24 h. Subsequently, the developed colonies with metallic blue coloration were considered ESBL-producers¹⁶.

Detection of TEM, SHV and CTX-M genes

The prevalence of the ESBL-encoding genes (*bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M}) was investigated using conventional PCR. Briefly, DNA extraction was conducted by boiling lysis method as previously described¹⁷. Amplification of DNA was performed in a GeneAmp 9700 PCR system (Applied Biosystems, USA) with primer sets listed in Table 1, according to previously described cycling parameters. After electrophoresis in a 1.5% agarose gel and DNA bands of expected sizes were gel-purified and sequenced¹⁸.

Table 1: Primer sequences for detection of ESBL genes

Target gene	Primer sequence (5' → 3')	Amplicon size (bp)	Reference
<i>bla</i> _{SHV}	F: TCGTTATGCGTTATATTCGCC	861	19
	R: GGTTAGCGTTGCCAGTGCT		
<i>bla</i> _{TEM}	F: TCGCCGCATACACTATTCTCAGAATGA	445	20
	R: ACGCTCACCGGCTCCAGATTTAT		
<i>bla</i> _{CTX-M}	F: ATGTGCAGYACCAGTAARGTKATGGC	593	21
	R: TGGGTRAARTARGTSACCAGAAAYCAGCGG		

Plant materials and extraction process

The plant materials (*Solenostemma argel*) were purchased from the local market in Egypt. After being washed with water, the argel leaves were dried and ground into a fine powder. Fifty grams of the powdered vegetative parts were added to 500 mL of ethanol and methanol, as separate treatments, and extracted using an ultrasonic homogenizer for 8 h at 25 °C. The extracts were subsequently filtered under a vacuum and concentrated using a rotary evaporator²². The concentrated extracts were stored at -4 °C until use.

Determination of total phenolics

The total phenolic content (TPC) in the argel extracts was quantified spectrometrically as described previously²³. In brief, 200 µL of the extract was mixed with 400 µL of Folin-Ciocalteu reagent and 4.0 mL distilled water. After incubation for 10 min at 25°C, 2 mL of saturated Na₂CO₃ solution was added, mixed, and incubated for 30 min. The absorbance was recorded at 765 nm using a Jenway 6300 spectrophotometer (Jenway, UK), and TPC was determined against a gallic acid calibration curve.

Determination of antioxidant activity

The antioxidant activity of the argel extracts was determined by estimating the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity according to a previously reported procedure^{24,25}. Briefly, 200 µL the extract was mixed with 1 mL of DPPH solution, and the mixture was incubated in the dark for 15 min. Subsequently, the absorbance was determined at 517 nm and the obtained results were expressed as percent inhibition (DPPH radical scavenging %).

Antibacterial activity against ESBL-producing *K. pneumoniae*

The MIC of each extract against ESBL-*Kp* was determined by the resazurin microtiter broth dilution method²⁶. The control strain *Klebsiella pneumoniae* ATCC 700603 was used in this test. Stock solutions of each plant extract were prepared and subjected to bifold serial dilution (ranging from 0.25 to 256 µg/mL) using Mueller–Hinton broth (Condalab, Spain) in 96-well microplates. Subsequently, a bacterial suspension (5×10^5 colony-forming units/mL) was prepared and 100 µL aliquots were dispensed into each well. The microtiter plates were incubated at 37 °C, for 24 h. Subsequently, 10 µL resazurin (0.5 mg/mL) were added to each well, and the plates were further incubated for 3 hrs at 37 °C. Afterward, MIC values were visually determined by observing the color change, the lowest concentration of each extract that prevented the change in the color of resazurin was recorded as the MIC²⁶.

RESULTS

In this study, 200 non-repetitive *Klebsiella* spp. isolates were identified by MALDI-TOF/MS. Results revealed that the vast majority (168/200; 84%) of the isolates were identified as *K. pneumoniae*, followed by *K. variicola* (19/200; 9.5%) and *K. oxytoca* (13/200; 6.5%). Because the main aim of this work is emphasis on *K. pneumoniae*, we selected *K. pneumoniae* isolates (n = 168) for further investigations and neglected the other *Klebsiella* species (n = 32).

The susceptibility of all *K. pneumoniae* isolates (n = 168) against 16 antibiotics was investigated using the Vitek 2 system and the antibiograms were tabulated (Table 2). The investigated *K. pneumoniae* isolates exhibited high resistance against most of the assessed antibiotics, especially, ampicillin, cefuroxime, and co-trimoxazole. Regarding aminoglycosides, 106 (63%) and 21 (12.5%) of the investigated isolates were resistant to gentamicin and amikacin, respectively. In addition, 71.4% of the isolates exhibited resistance to cefotaxime. Furthermore, the isolates showed remarkable resistance to cefuroxime (83.9%), ampicillin–sulbactam (72%), ciprofloxacin (58.3%), ceftazidime (55.3%), aztreonam (44%), and cefepime (36.3%), respectively. The low resistance rates were observed against ceftazidime (11.9%) and meropenem (11.3%).

Table 2: Antibiotic susceptibility pattern of *K. pneumoniae* isolates (n = 168)

Antibiotics class/Category		Antibiotic	Antibiotic susceptibility		
			Resistant % (n)	Intermediate % (n)	Susceptible % (n)
Beta-lactams	Penicillin	Ampicillin	91 % (153)	0	8.9% (15)
	Beta-lactam combination agents	Piperacillin-Tazobactam	17.8 % (30)	14.2 % (24)	67.8 (114)
		Amoxicillin-clavulanate	41.6 % (70)	22.6 % (38)	35.7 % (60)
		Ampicillin–Sulbactam	72 % (121)	3.5 % (6)	24.4 % (41)
		Cephameycins	Cefoxitin	11.9 % (20)	1.8 % (3)
	2 nd generation cephalosporins	Cefuroxime	83.9 % (141)	5.3 % (9)	10.7 % (18)
	3 rd generation cephalosporins	Cefotaxime	71.4 % (120)	7.7 % (13)	20.8% (35)
		Ceftazidime	55.3% (93)	2.3 (4)	42.2 % (71)
	4 th generation cephalosporins	Cefepime	36.3 % (61)	16 % (27)	47.6 % (80)
	Monobactams	Aztreonam	44 % (74)	1.2 % (2)	54.7 % (92)
Aminoglycosides	Amikacin	12.5 % (21)	2.3 % (4)	85.1 % (143)	
	Gentamicin	63 % (106)	1.8 % (3)	35.1 % (59)	
Quinolones	Ciprofloxacin	58.3 % (98)	3.5 % (6)	38.1 % (64)	
Folate pathway antagonist	Co-trimoxazole	96.4 % (162)	0	3.5 % (6)	
Carbapenems	Meropenem	11.3 % (19)	1.2 % (2)	87.5 % (147)	
Nitrofurans	Nitrofurantoin	38.7 % (65)	18.4 % (31)	42.8 % (72)	

In this work, the phenotypic detection of ESBLs among the *K. pneumoniae* isolates was performed by CHROMagar ESBL. Of the investigated 168 isolates, 48 (28.5%) exhibited good growth with metallic blue coloration indicating the production of ESBL (Figure 1). Accordingly, ESBL-*Kp* isolates were selected and subjected to molecular studies. The phenotypically confirmed ESBL-*Kp* isolates (n = 48) were further characterized using conventional PCR to detect the presence of ESBLs-coding genes (Figure 2). Results revealed that all the investigated ESBL-*Kp* harbor the *bla*_{SHV} gene. The majority of isolates (42/48; 87.5%) were positive for *bla*_{CTX-M} while *bla*_{TEM} gene was detected in 45.8% of the investigated ESBL-*Kp* isolates (22/48).




Fig. 1: Phenotypic detection of ESBL using CHROMagar ESBL. The upper part shows the typical growth of ESBL-*Kp* with the characteristic blue color. The lower part shows typical growth of *K. pneumoniae* on MacConkey agar.



Fig. 2: Agarose gel electrophoresis showing *bla*_{SHV}, *bla*_{CTX-M} and *bla*_{TEM}

PCR products amplified from ESBL-producing *K. pneumoniae* isolates

Herein, we performed ultrasonic-assisted methanolic and ethanolic extraction of argel leaves, and the chemical and biological properties of the extracts were assessed. The TPC of the ethanolic and methanolic

extracts were 57.3 and 79.5 mg/g, respectively. Both extracts demonstrated considerable antioxidant activity, however the methanolic extract has superior antioxidant activity, compared with that of the ethanolic one (Table 3).

Table 3: Antioxidant activity of ethanolic and methanolic extracts of argel leaves

Concentration (µg/mL)	DPPH radical scavenging activities (%)	
	Ethanolic extract	Methanolic extract
20	35.6	55.1
40	54.6	69.1
60	66.3	78.2
80	73.4	84.6
100	82.4	95.3

Concerning the antimicrobial activity, we found that *S. argel* extracts had potent antibacterial activity against ESBL-*Kp* isolates. Results demonstrated that the MIC of the ethanolic extract against various ESBL-*Kp* isolates ranged from 8 to 32 µg/mL while that of the methanolic extract ranged from 1 to 16 µg/mL. The ethanolic and methanolic extracts of *S. argel* leaves inhibited *Klebsiella pneumoniae* ATCC 700603 with MIC values of 16 and 2 µg/mL, respectively.

DISCUSSION

Monitoring antibiotic resistance rates is crucial for developing empirical treatment techniques and evaluating the current guidelines. Moreover, searching for green and natural antimicrobial agents as potential alternatives to antibiotics could be a promising approach to combat the rapid emergence of the antibiotic resistance crisis. This study addresses the antibiogram of *K. pneumoniae* isolates and the phenotypic and genotypic assessment of ESBL-producing isolates. Furthermore, we investigated the antibacterial efficacy of ethanolic and methanolic extracts of argel leaves against ESBL-*Kp* isolates. In this study, *K. pneumoniae* isolates exhibited notable resistance levels to β-lactam antibiotics including penicillin (91%), cefuroxime (83.9%), ciprofloxacin (58.3%), ceftazidime (55.3%), aztreonam (44%), and cefepime (36.3%). These results agree with previous studies reporting the high resistance levels of *K. pneumoniae* isolates against β-lactam antibiotics^{27,28}. It is worth noting that 11.3% of our isolates were carbapenem-resistant, exhibiting resistance against meropenem. The carbapenems are usually considered as last line of defence against severe bacterial infections, especially with MDR bacteria²⁹. In an attempt to characterize the ESBL-*Kp* isolates at

molecular level, we investigated the prevalence of three ESBL-coding genes. We found that most isolates (87.5%) were positive for *bla*_{CTX-M} while the *bla*_{TEM} gene was detected in 45.8% of the investigated ESBL-*Kp* isolates. These results harmony recent studies reporting that *bla*_{SHV} and *bla*_{CTX-M} were the most prevalent ESBL-coding genes acquired by almost all ESBL-*Kp* isolates with a relatively low prevalence of *bla*_{TEM} gene³⁰. In a recent study conducted on *K. pneumoniae* isolated from patients admitted to the Urology & Nephrology Center in Egypt, the prevalence of *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M} were 80, 70, and 63.3%, respectively³¹. The sulfhydryl reagent variable (SHV) β -lactamases have the ability to hydrolyze oxacillin and cloxacillin and are not inhibited by clavulanate acid and provide extraordinary resistance against β -lactam antibiotics³². Antibiotic-resistant bacteria that are challenging to treat require developing of novel therapeutics and approaches, such as using adjuvants, natural products, bacteriophages, antimicrobial peptides, and nanoparticles.

In this work, the TPC extracted from argel leaves is relatively higher than those reported in previous studies³³. The improved recovery of phenolic content by the ultrasonic-assisted extraction approach could be due to the breakage of plant cells by ultrasound waves, resulting in the easier release of the cellular contents into the solvent. Also, the discrepancy in the phenolic content of extracts could be attributed to the differences in the growing environment, growth stage, and harvesting time³⁴. Moreover, we observed the increased scavenging potency with the increasing argel concentration, and the highest antioxidant activity (95.3%) was achieved by using methanolic extract of argel leaves (100 μ g/mL). These observations are consistent with previous investigation that stated the efficacy of methanol as a promising solvent to extract phenolics and antioxidant compounds from *S. argel*³⁵. It has been proposed that the antioxidant activity of *S. argel* extracts is because of the existence of phenolic acids such as sinapic acid, p-coumaric, ferulic, and 4-hydroxybenzoic acids as well as glycosylated flavonoids, polyphenols, β -carotene, and monoterpenes^{22,36}. Besides the powerful antioxidant activity, this investigation sheds light on the antibacterial effects of the argel extracts against ESBL-*Kp*. Likewise, extracts of argel were reported as promising antibacterial agents against *E. coli*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Enterobacter cloacae*, *Acinetobacter baumannii*³³. Argel is known to have diverse phenolics including caffeoylquinic acid, feruloylquinic acid and vanillate glucoside which could be play a crucial role in inhibiting these microbes³⁷. According to previous reports, argel extracts contain various flavonoidal compounds with antimicrobial activity such as catechin and kaempferol³⁸. Along with

phenolics and flavonoids, a recent study demonstrated the antibacterial antibiofilm activity of argel against *Salmonella enterica* serotype *typhimurium* is attributed to the presence of a steroidal glycoside called stemmoside C³⁹. In a recent report, argel extract has demonstrated activity against *Salmonella typhimurium*, *Bacillus subtilis*, *E. coli*, *P. aeruginosa*, and *Listeria innocua*⁴⁰. In a comparable investigation, it was found that argel extract displayed significant antibacterial properties and reduced the formation of biofilms in *S. aureus*¹³. One limitation of our study was that the cytotoxicity of the argel extract was not assessed. Also, the antibacterial mechanism was not investigated in comparison to standard antibiotics.

CONCLUSION

This investigation shed light on the elevated levels of resistance among clinical *K. pneumoniae* isolates and highlighted the presence of *bla*_{SHV} gene by all inspected ESBL-*Kp*. Moreover, the study verified the potent antibacterial activity of the methanolic and ethanolic extracts of argel against ESBL-*Kp* and indicated the superior antibacterial activity of the methanolic extract with MIC values ranging from 1 to 16 μ g/mL. These findings suggested that methanolic extract of argel is a potential candidate for combating ESBL-*Kp*. In conclusion, using argel extract as a sustainable antimicrobial agent to counteract ESBL would mitigate antibiotic resistance and promote its future therapy implementation.

Declarations:

Ethical Approval: Not applicable, because this article does not contain any human participants, data or tissues.

Consent for publication: Not applicable

Acknowledgment: Not applicable

Conflicts of Interest: The authors declare no conflict of interest.

Funding: Authors did not receive any grants from funding agencies.

Availability of data and material: Data is provided within the manuscript and other data are available upon request.

REFERENCES

1. Hammoudi Halat D, Ayoub Moubareck C. Hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19. *F1000Research* 2024 12:92, 2024; 12, 92. doi:10.12688/f1000research.129080.2
2. Lei T yu, Liao B bin, Yang LR, Wang Y, Chen X bing. Hypervirulent and carbapenem-resistant

- Klebsiella pneumoniae*: A global public health threat. *Microbiological Research*, 2024; 288, 127839. doi:10.1016/J.MICRES.2024.127839
3. Rahmat Ullah S, Jamal M, Rahman A, Andleeb S. Comprehensive insights into *Klebsiella pneumoniae*: unravelling clinical impact, epidemiological trends and antibiotic-resistance challenges. *Journal of Antimicrobial Chemotherapy*, 2024; 79(7), 1484-1492. doi:10.1093/JAC/DKAE184
 4. Chen J, Allel K, Zhuo C, et al. Extended-Spectrum β -Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae*: Risk Factors and Economic Burden Among Patients with Bloodstream Infections. *Risk Management and Healthcare Policy*, 2024; 17, 375-385. doi:10.2147/RMHP.S453686
 5. Fadl MG, Farahat MG, Mohamed ZK. Optimum Biosorption and Resistance of Uranium by Metal-Resistant Bacteria Isolated from Rock Ore. *Geomicrobiology Journal*, 2022; 39(8), 689-696. doi:10.1080/01490451.2022.2069892
 6. Ramadan RA, Bedawy AM, Negm EM, et al. Carbapenem-Resistant *Klebsiella pneumoniae* Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics. *Infection and Drug Resistance*, 2022; 15, 3537-3548. doi:10.2147/IDR.S371248
 7. Romyasamit C, Sornsene P, Kawila S, Saengsuwan P. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: insights from a tertiary hospital in Southern Thailand. *Microbiology Spectrum*, 2024; 12(7). doi:10.1128/SPECTRUM.00213-24
 8. Alsheikh HM Al, Sultan I, Kumar V, et al. Plant-Based Phytochemicals as Possible Alternative to Antibiotics in Combating Bacterial Drug Resistance. *Antibiotics*, 2020; 9(8), 480. doi:10.3390/ANTIBIOTICS9080480
 9. Singha B, Singh V, Soni V. Alternative therapeutics to control antimicrobial resistance: a general perspective. *Frontiers in Drug Discovery*, 2024; 4, 1385460. doi:10.3389/FDSSV.2024.1385460
 10. Vaou N, Stavropoulou E, Voidarou C, Tsigalou C, Bezirtzoglou E. Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives. *Microorganisms*, 2021; 9(10), 2041. doi:10.3390/MICROORGANISMS9102041
 11. Guedes BN, Krambeck K, Durazzo A, et al. Natural antibiotics against antimicrobial resistance: sources and bioinspired delivery systems. *Brazilian Journal of Microbiology* 2024, Published online June 18, 2024, 1-14. doi:10.1007/S42770-024-01410-1
 12. El-Zayat MM, Eraqi MM, Alfaiz FA, Elshaer MM. Antibacterial and antioxidant potential of some Egyptian medicinal plants used in traditional medicine. *Journal of King Saud University - Science*, 2021; 33(5), 101466. doi:10.1016/J.JKSUS.2021.101466
 13. Alkuwayti MA. Anti-Staphylococcus aureus Activity of the Aqueous Ethanol Extract of *Solenostemma argel* Aerial Parts. *Journal of Pure and Applied Microbiology*, 2023; 17(4), 2581. doi:10.22207/JPAM.17.4.55
 14. Sharaf SMA, Ali HTA, Salah MG, Kamel Z. Insight on the Prevalence of Clinical *Klebsiella* Isolates Producing Extended Spectrum Beta-Lactamases. *Egyptian Journal of Medical Microbiology*, 2024; 33(3), 125-131. doi:10.21608/EJMM.2024.298504.1267
 15. Farahat MG. Enhancement of β -Cyclodextrin Production and Fabrication of Edible Antimicrobial Films Incorporated with Clove Essential Oil/ β -cyclodextrin Inclusion Complex. *Microbiology and Biotechnology Letters*, 2020; 48(1), 12-23. doi:10.4014/MBL.1909.09016
 16. El Aila NA, Al Laham NA, Ayesha BM. Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip. *BMC infectious diseases*, 2023; 23(1), 99. doi:10.1186/S12879-023-08017-1
 17. Ghaith DM, Mohamed ZK, Farahat MG, Aboukasem Shahin W, Mohamed HO. Colonization of intestinal microbiota with carbapenemase-producing Enterobacteriaceae in paediatric intensive care units in Cairo, Egypt. *Arab Journal of Gastroenterology*, 2019; 20(1), 19-22. doi:10.1016/J.AJG.2019.01.002
 18. Kamel Z, Mohamed NM, Farahat MG. Optimization of culture conditions for production of B-galactosidase by *Bacillus megaterium* NM56 isolated from raw milk. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 2016; 7(1), 366-376.
 19. Saha O, Basri R, Hossain MA, Sultana M. Characterization of multidrug and heavy metal resistance of carbapenemases producing *Klebsiella pneumoniae* from poultry samples in Bangladesh. *Veterinary Medicine and Science*, 2023; 9(4), 1685-1701. doi:10.1002/VMS3.1168
 20. Ballén V, Gabasa Y, Ratia C, Ortega R, Tejero M, Soto S. Antibiotic Resistance and Virulence Profiles of *Klebsiella pneumoniae* Strains Isolated From Different Clinical Sources. *Frontiers in*

- Cellular and Infection Microbiology, 2021; 11, 1. doi:10.3389/FCIMB.2021.738223
21. Kiiru J, Kariuki S, Goddeeris BM, Butaye P. Analysis of β -lactamase phenotypes and carriage of selected β -lactamase genes among *Escherichia coli* strains obtained from Kenyan patients during an 18-year period. *BMC Microbiology*, 2012; 12(1), 1-11. doi:10.1186/1471-2180-12-155
 22. Mohamed Ahmed IA, Al-Juhaimi F, Adisa AR, et al. Optimization of ultrasound-assisted extraction of phenolic compounds and antioxidant activity from Argel (*Solenostemma argel* Hayne) leaves using response surface methodology (RSM). *Journal of Food Science and Technology*, 2020; 57(8), 3071-3080. doi:10.1007/S13197-020-04340-6
 23. Kalpoutzakis E, Chatzimitakos T, Athanasiadis V, et al. Determination of the Total Phenolics Content and Antioxidant Activity of Extracts from Parts of Plants from the Greek Island of Crete. *Plants*, 2023; 12(5), 1092. doi:10.3390/PLANTS12051092
 24. Farahat MG. Enhanced anti-oxidant activity of neoagarooligosaccharides produced by β -agarase derived from *Aquimarina agarilytica* NI125. *Novel Research in Microbiology Journal*, 2019; 3(6), 511-525. doi:10.21608/NRMJ.2019.66744
 25. Abd El-Ghany MN, Hamdi SA, Elbaz RM, et al. Development of a Microbial-Assisted Process for Enhanced Astaxanthin Recovery from Crab Exoskeleton Waste. *Fermentation*, 2023; 9(6), 505. doi:10.3390/FERMENTATION9060505
 26. Sayed FM, El-Rouby MN, Kamel Z, Farahat MG. Cytotoxicity and antibacterial activity of actinomycetes-mediated biogenic silver nanoparticles against methicillin-resistant *Staphylococcus aureus* (MRSA). *Egyptian Journal of Medical Microbiology*, 2024; 33(4). doi:10.21608/EJMM.2024.307218.1290
 27. Andrew B, Kagirita A, Bazira J. Prevalence of Extended-Spectrum Beta-Lactamases-Producing Microorganisms in Patients Admitted at KRRH, Southwestern Uganda. *International Journal of Microbiology*, 2017; 2017(1), 3183076. doi:10.1155/2017/3183076
 28. Siriphap A, Kittit T, Khuekankaew A, et al. High prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates: A 5-year retrospective study at a Tertiary Hospital in Northern Thailand. *Frontiers in Cellular and Infection Microbiology*, 2022; 12, 955774. doi:10.3389/FCIMB.2022.955774
 29. Parker JK, Gu R, Estrera GA, et al. Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas. *Infection and Drug Resistance*, 2023; 16, 1249-1261. doi:10.2147/IDR.S403448
 30. Al-Sheboul SA, Al-Madi GS, Brown B, Hayajneh WA. Prevalence of Extended-Spectrum β -Lactamases in Multidrug-Resistant *Klebsiella pneumoniae* Isolates in Jordanian Hospitals. *Journal of Epidemiology and Global Health*, 2023; 13(2), 180-190. doi:10.1007/S44197-023-00096-2
 31. Hamed H, Gaber A, EL Sehsah EM, Author C, Hamed Saleh H. Detection of β -lactamase genes (*bla*TEM, *bla* CTX-M and *bla* SHV) in uropathogens isolated from patients with UTI. *Egyptian Journal of Medical Microbiology*, 2021; 30(3), 97-103. doi:10.51429/EJMM30313
 32. Liakopoulos A, Mevius D, Ceccarelli D. A review of SHV extended-spectrum β -lactamases: Neglected yet ubiquitous. *Frontiers in Microbiology*, 2016; 7(SEP), 219996. doi:10.3389/FCIMB.2016.01374
 33. Elsanhoty RM, Soliman MSM, Khidr YA, et al. Pharmacological Activities and Characterization of Phenolic and Flavonoid Compounds in *Solenostemma argel* Extract. *Molecules*, 2022; 27(23), 8118. doi:10.3390/MOLECULES27238118
 34. Al-Juhaimi FY, Mohamed Ahmed IA, Adiamo OQ, et al. Effect of Argel (*Solenostemma argel*) leaf powder on the quality attributes of camel patties during cold storage. *Journal of Food Processing and Preservation*, 2018; 42(2), e13496. doi:10.1111/JFPP.13496
 35. Muddathir AM, Yamauchi K, Batubara I, Mohieldin EAM, Mitsunaga T. Anti-tyrosinase, total phenolic content and antioxidant activity of selected Sudanese medicinal plants. *South African Journal of Botany*, 2017; 109, 9-15. doi:10.1016/J.SAJB.2016.12.013
 36. Al-Juhaimi FY, Shahzad SA, Ahmed AS, et al. Effect of Argel (*Solenostemma argel*) leaf extract on quality attributes of chicken meatballs during cold storage. *Journal of Food Science and Technology*, 2018; 55(5), 1797-1805. doi:10.1007/S13197-018-3094-1
 37. El-Shiekh RA, Salem MA, Mouneir SM, Hassan A, Abdel-Sattar E. A mechanistic study of *Solenostemma argel* as anti-rheumatic agent in relation to its metabolite profile using UPLC/HRMS. *Journal of Ethnopharmacology*, 2021; 265, 113341. doi:10.1016/J.JEP.2020.113341
 38. Benmaarouf DK, Pinto DCGA, China B, Zenia S, Bendesari KB, Ben-Mahdi MH. Chemical analysis, antioxidant, anti-inflammatory and antinociceptive effects of acetone extract of Algerian *Solenostemma argel* (delile) hayne leaves. *International Journal of Current Pharmaceutical*

Research, Published online September 15, 2020, 72-81. doi:10.22159/IJCPR.2020V12I5.39771

39. El-Shiekh RA, Elshimy R. Therapeutic effects of Stemmoside C against *Salmonella enterica* serotype typhimurium infected BALB/c mice. *Steroids*, 2023; 199, 109296. doi:10.1016/J.STEROIDS.2023.109296
40. Abdel-Sattar E, El-Shiekh RA. A Comprehensive Review on *Solenostemma argel* (Del.) Hayne, An Egyptian Medicinal Plant. *Bulletin of Faculty of Pharmacy Cairo University*, 2024; 62(1), 3. doi:10.54634/2090-9101.1050.